Em recrutamento
FASE
Número Europeu 2022-502548-12-00
BGB-3111-308 MAHOGANY
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Detalhes
Destaques